End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.89 CNY | +0.45% | +2.52% | +13.94% |
01:00am | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
01:00am | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
Business Summary
Number of employees: 8,933
Sales per Business
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Chemical Agents
52.9
%
| 7,000 | 55.4 % | 6,571 | 52.9 % | -6.13% |
APIs and Intermediates
26.2
%
| 3,138 | 24.8 % | 3,253 | 26.2 % | +3.66% |
Traditional Chinese Medicine
14.0
%
| 1,254 | 9.9 % | 1,745 | 14.0 % | +39.19% |
Diagnostic Reagents and Equipment
5.3
%
| 724 | 5.7 % | 659 | 5.3 % | -8.92% |
Biological
0.7
%
| 408 | 3.2 % | 84 | 0.7 % | -79.33% |
Other Business
0.4
%
| 42 | 0.3 % | 49 | 0.4 % | +18.26% |
Sales Materials, Processing Fees, Etc.
0.4
%
| - | - | 46 | 0.4 % | - |
Others
0.1
%
| - | - | 14 | 0.1 % | - |
Rental
0.1
%
| 7 | 0.1 % | 9 | 0.1 % | +29.96% |
Sales per region
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
87.3
%
| 10,959 | 87.5 % | 10,754 | 87.3 % | -1.86% |
Overseas
12.7
%
| 1,565 | 12.5 % | 1,571 | 12.7 % | +0.40% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Yang Gang Tang
PSD | President | 55 | 18-07-16 |
Yan Xia Si
DFI | Director of Finance/CFO | 56 | 93-03-31 |
Maolin Wang
CHM | Chairman | 59 | 00-12-31 |
Bao Guo Zhu
CHM | Chairman | 62 | 01-12-31 |
Guo Xiang Xu
BRD | Director/Board Member | 61 | 07-02-28 |
De Sheng Tao
BRD | Director/Board Member | 60 | 84-12-31 |
De Long Ye
IRC | Investor Relations Contact | - | - |
Yu Xuan Huang
PRN | Corporate Officer/Principal | 57 | 18-10-24 |
Dai Hong Yang
PRN | Corporate Officer/Principal | 58 | 96-12-31 |
Liang Yang
SEC | Corporate Secretary | 41 | 11-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bao Guo Zhu
CHM | Chairman | 62 | 01-12-31 |
Qiu Sheng Tian
BRD | Director/Board Member | 68 | 19-10-14 |
Hua Min Huang
BRD | Director/Board Member | 53 | 13-05-31 |
De Sheng Tao
BRD | Director/Board Member | 60 | 84-12-31 |
Guo Xiang Xu
BRD | Director/Board Member | 61 | 07-02-28 |
Xiong Yu
BRD | Director/Board Member | 63 | 13-08-31 |
Hua Bai
BRD | Director/Board Member | 55 | 20-06-29 |
Hui Yuan Luo
BRD | Director/Board Member | 57 | 21-07-05 |
Yin Tang
BRD | Director/Board Member | 49 | 15-12-28 |
Yang Gang Tang
PSD | President | 55 | 18-07-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 310,011,513 | 0 | 2,476,300 ( 0.7988 %) | 38.45 % |
Stock B | 1 | 621,252,025 | 358,051,918 ( 57.63 %) | 2,152,600 ( 0.3465 %) |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
5,829,048 | 0.96% | 32,278,528 $ |
Company contact information
Livzon Pharmaceutical Group, Inc.
Headquarters Building 38 Chuangye North Road
519090, Zhuhai
+86 75 6813 5888
http://www.livzon.com.cnSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.94% | 4.45B | |
+43.32% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+18.96% | 328B | |
+8.10% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.19% | 167B | |
+6.01% | 165B |
- Stock Market
- Equities
- 000513 Stock
- Company Livzon Pharmaceutical Group Inc.